The State of America's Direct Support Workforce Crisis 2026

New data reveal little sign of meaningful progress ahead of impending wave of funding cuts.
Explore the Research
May 20, 2025
Partner Presentation

Health Care Resource Utilization (HCRU) Before and After the Initiation of Cannabidiol Among Those With Refractory Epilepsies

Share this page
Share this page
In Partnership with
May 20, 2025
2:00pm-3:00pm EST

Join the Meeting on May 20

Join ANCOR Diamond Partner Jazz Pharmaceuticals on May 20 for this important presentation on Health Care Resource Utilization (HCRU) Before and After the Initiation of Cannabidiol Among Commercial and Medicaid Patients with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS), Tuberous Sclerosis Complex (TSC) and other Refractory Epilepsies.

Presentation objectives:

  • Discuss HCRU and Medical costs before and after Epidiolex® (cannabidiol) initiation
  • Review anti-seizure medicine and anxiolytic medication use before and after Epidiolex® (cannabidiol) initiation

Presenter

  • Michael Faithe, Director, Payer Value & Outcomes, Jazz Pharmaceuticals